Intravitreal AAV2.COMP-Ang1 prevents neurovascular degeneration in a murine model of diabetic retinopathy

Diabetes

Volumn 64, Issue 12, 2015, Pages 4247-4259

  Cahoon, Judd M ^a   Rai, Ruju R ^a   Carroll, Lara S ^a   Uehara, Hironori ^a   Zhang, Xiaohui ^a   O'Neil, Christina L ^b   Medina, Reinhold J ^b   Das, Subtrata K ^a   Muddana, Santosh K ^a   Olson, Paul R ^a   Nielson, Spencer ^a   Walker, Kortnie ^a   Flood, Maggie M ^a   Messenger, Wyatt B ^a   Archer, Bonnie J ^a   Barabas, Peter ^a   Krizaj, David ^a   Gibson, Christopher C ^c   Li, Dean Y ^a   Koh, Gou Y ^d   Gao, Guangping ^e   Stitt, Alan W ^b   Ambati, Balamurali K ^a   more..

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF UTAH   (United States)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; PARVOVIRUS VECTOR; ANGPT1 PROTEIN, HUMAN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COMP PROTEIN, HUMAN; HYBRID PROTEIN;

ADENO ASSOCIATED VIRUS 2; AKITA MOUSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL INTERACTION; COLONY FORMING CELL; CONTROLLED STUDY; DENSITY; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; ENDOTHELIUM CELL; ENGRAFTMENT; HUMAN; HUMAN CELL; LEUKOCYTE; LEUKOSTASIS; MOUSE; MURINE MODEL; NERVE DEGENERATION; NEUROPHYSIOLOGICAL MONITORING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA BLOOD VESSEL; RETINAL THICKNESS; TISSUE OXYGENATION; TISSUE REGENERATION; VIRAL GENE THERAPY; VISION; VISUAL DISORDER; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; COMPLICATION; CROSS BREEDING; CYTOLOGY; DISEASE MODEL; ENDOTHELIAL PROGENITOR CELL; GENE THERAPY; GENETICS; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; MULTIMODALITY CANCER THERAPY; MUTANT MOUSE STRAIN; PATHOLOGY; PROTEIN STABILITY; RANDOMIZATION; RETINA; SOLUBILITY; TRANSPLANTATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOPOIETIN-1; ANIMALS; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CELLS, CULTURED; COMBINED MODALITY THERAPY; CROSSES, GENETIC; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; ENDOTHELIAL PROGENITOR CELLS; GENETIC THERAPY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTRAVITREAL INJECTIONS; LEUKOCYTES; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PROTEIN STABILITY; RANDOM ALLOCATION; RECOMBINANT FUSION PROTEINS; RETINA; SOLUBILITY;

EID: 84962191237     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1030     Document Type: Article

References (50)

1. Yau JWY, Rogers SL, Kawasaki R, et al.; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-564
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27: 1047-1053
3. Frank RN. Diabetic retinopathy. N Engl J Med 2004;350:48-58
4. Agarwal A, Sarwar S, Sepah YJ, Nguyen QD. What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era? Curr Opin Ophthalmol 2015;26:177-183
5. Mitchell P, Bandello F, Schmidt-Erfurth U, et al.; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-625
6. Heier JS, Boyer D, Nguyen QD, et al.; CLEAR-IT 2 Investigators. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118: 1098-1106
7. Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology 2014;121:1783-1789
8. Elman MJ, Aiello LP, Beck RW, et al.; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.e35
9. Dornan T, Mann JI, Turner R. Factors protective against retinopathy in insulin-dependent diabetics free of retinopathy for 30 years. Br Med J (Clin Res Ed) 1982;285:1073-1077
10. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001;158:147-152
11. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-1452
12. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996;97: 2883-2890
13. Hammes H-P, Lin J, Wagner P, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004;53:1104-1110
14. van Dijk HW, Kok PHB, Garvin M, et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci 2009;50:3404-3409
15. Patel JI, Hykin PG, Gregor ZJ, Boulton M, Cree IA. Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol 2005;89:480-483
16. Gavard J, Patel V, Gutkind JS. Angiopoietin-1 prevents VEGF-induced en-dothelial permeability by sequestering Src through mDia. Dev Cell 2008;14:25-36
17. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-463
18. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165-177
19. Joussen AM, Poulaki V, Tsujikawa A, et al. Suppression of diabetic reti-nopathy with angiopoietin-1. Am J Pathol 2002;160:1683-1693
20. Cho C-H, Kammerer RA, Lee HJ, et al. COMP-Ang1: a designed angio-poietin-1 variant with nonleaky angiogenic activity. Proc Natl Acad Sci U S A 2004;101:5547-5552
21. Syrjälä SO, Nykänen AI, Tuuminen R, et al. Donor heart treatment with COMP-Ang1 limits ischemia-reperfusion injury and rejection of cardiac allografts. Am J Transplant 2015;15:2075-2084
22. Moon HE, Byun K, Park HW, et al. COMP-Ang1 Potentiates EPC Treatment of Ischemic Brain Injury by Enhancing Angiogenesis Through Activating AKT-mTOR Pathway and Promoting Vascular Migration Through Activating Tie2-FAK Pathway. Exp Neurobiol 2015;24:55-70
23. Kim DH, Jung YJ, Lee AS, et al. COMP-angiopoietin-1 decreases lipo-polysaccharide-induced acute kidney injury. Kidney Int 2009;76:1180-1191
24. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005;46:2210-2218
25. Han Z, Guo J, Conley SM, Naash MI. Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy. Invest Ophthalmol Vis Sci 2013;54:574-584
26. Zhu W, London NR, Gibson CC, et al. Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability. Nature 2012;492: 252-255
27. Medina RJ, O'Neill CL, Devine AB, Gardiner TA, Stitt AW. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS One 2008;3:e2584
28. Medina RJ, O'Neill CL, O'Doherty TM, et al. Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8. Mol Med 2011;17:1045-1055
29. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18:643-650
30. Zhang X, Das SK, Passi SF, et al. AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization. Mol Ther 2015;23:226-234
31. Yin L, Greenberg K, Hunter JJ, et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011;52:2775-2783
32. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961;66:366-378
33. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-1169
34. Uemura A, Ogawa M, Hirashima M, et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 2002;110:1619-1628
35. Thurston G. Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J Anat 2002;200:575-580
36. Huang H, Gandhi JK, Zhong X, et al. TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci 2011;52: 1336-1344
37. Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM. Leukocytes in diabetic retinopathy. Curr Diabetes Rev 2007;3:3-14
38. Vinores SA, Xiao W-H, Shen J, Campochiaro PA. TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol 2007;182:73-79
39. Cahoon JM, Olson PR, Nielson S, et al. Acridine orange leukocyte fluo-rography in mice. Exp Eye Res 2014;120:15-19
40. Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000;156:1733-1739
41. Gastinger MJ, Kunselman AR, Conboy EE, Bronson SK, Barber AJ. Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice. Invest Ophthalmol Vis Sci 2008;49:2635-2642
42. Aung MH, Kim MK, Olson DE, Thule PM, Pardue MT. Early visual deficits in streptozotocin-induced diabetic long evans rats. Invest Ophthalmol Vis Sci 2013; 54:1370-1377
43. Hombrebueno JR, Chen M, Penalva RG, Xu H. Loss of synaptic connectivity, particularly in second order neurons is a key feature of diabetic retinal neuropathy in the Ins2Akita mouse. PLoS One 2014;9:e97970
44. Caballero S, Hazra S, Bhatwadekar A, et al. Circulating mononuclear progenitor cells: differential roles for subpopulations in repair of retinal vascular injury. 2013;54:3000-3009
45. Medina RJ, O'Neill CL, Humphreys MW, Gardiner TA, Stitt AW. Outgrowth endothelial cells: characterization and their potential for reversing ischemic ret-inopathy. Invest Ophthalmol Vis Sci 2010;51:5906-5913
46. Medina RJ, O'Neill CL, Sweeney M, et al. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med Genomics 2010;3:18
47. Shen F, Walker EJ, Jiang L, et al. Coexpression of angiopoietin-1 with VEGF increases the structural integrity of the blood-brain barrier and reduces atrophy volume. J Cereb Blood Flow Metab 2011;31:2343-2351
48. Lee J, Kim KE, Choi D-K, et al. Angiopoietin-1 guides directional angio-genesis through integrin avb5 signaling for recovery of ischemic retinopathy. Sci Transl Med 2013;5:203ra127-7
49. Shin HY, Lee YJ, Kim HJ, et al. Protective role of COMP-Ang1 in ischemic rat brain. J Neurosci Res 2010;88:1052-1063
50. Gastinger MJ, Singh RSJ, Barber AJ. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 2006;47:3143-3150